Feed COCP
CO

Cocrystal Pharma, Inc.

COCP · NASDAQ

$1.19 +3.03% (+$0.04)
1M +9.01%
Market Cap $17.0M
P/E Ratio -
Div. Yield -
ROE 207.47%

Bulios Fair Price

$0.84

29.4% downside

Trenutna cena

$1.19

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica COCP trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 51.39x
P/B 16.24x
P/E N/A
Growth
0 /100
Declining
Book val. growth 45.71%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Gross margin 205.76%
FCF margin 2,470.67%
Net margin 3,011.52%
Quality
1 /100
Poor
ROIC 423.90%
Asset turnover 0.07x
ROE 207.47%
Debt
45 /100
Moderate
Debt/Equity 1.28x
Current ratio 1.24x
Int. coverage N/A
Stability
14 /100
Unstable
Beta 1.48x
Profitable years 0
EPS volatility 52,252.30%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o COCP
Online

O podjetju

Cocrystal Pharma, Inc. (COCP) is a biotechnology company focusing on the discovery and development of antiviral drug compounds to combat infectious diseases. The company specializes in developing therapeutic products that target the inhibition of virus replication and prevent their spread. Cocrystal Pharma develops drugs for various viral infections, including diseases like influenza, upper respiratory tract infections, and more. The company utilizes structural biology and computational modeling to design effective drug compounds. With the growing significance of antiviral drugs and the need for new treatment options, Cocrystal Pharma, Inc. has the potential for sustained growth. Cocrystal Pharma, Inc. (COCP) shares might be an interesting choice for investors seeking involvement in the biotechnology and antiviral therapeutic therapies industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

James E. Sapirstein

Employees

10

Headquarters

Bothell

Prihajajoči dogodki

13 NOV.

Earnings

Upcoming earnings report

53d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.